基因代理的葡萄糖样-1受体激动剂与管管间炎的风险有关:一个网络孟德尔随机化研究
Xu-Chun Xu1, Fang-Zhong Huang1, Jun Ying1
1Department of Nephrology, Jinhua Hospital Affiliated to Zhejiang University School of Medicine, Zhejiang Province, China.
Medicine
|September 24, 2025
概括
类似葡萄糖类-1受体激动剂可能会增加慢性管间性炎的风险. 这项研究使用了基因分析来发现因果关系,突出了这些糖尿病药物患者的潜在脏风险.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药物基因组学 药物基因组学
- 内分泌学 在内分泌学.
背景情况:
- 类似葡萄糖类-1受体激动剂 (GLP1RAs) 对于2型糖尿病 (T2DM) 管理至关重要,提供血糖和心脏脏的好处.
- 新出现的证据表明GLP1RAs可能对脏健康构成风险,特别是管间性炎 (TIN).
研究的目的:
- 调查使用类似葡萄糖-1受体激动剂和管-间歇性炎风险之间的潜在因果关系.
- 确定潜在的介导性血蛋白和参与这种关联的生物途径.
主要方法:
- 用GLP1R效应的遗传代理进行了双样本的门德尔随机化 (MR) 分析.
- 用英国生物银行制药蛋白质组项目数据进行了全蛋白质组MR和调解分析.
- 使用局部化分析来评估GLP1R表达和CTIN之间的共享遗传变异.
主要成果:
- 核磁共振分析显示GLP1RA使用与慢性管间性炎 (CTIN) (OR=2.32,P=0.001) 之间存在显著的因果关系.
- 在GLP1RA使用和急性管间性炎 (ATIN) (OR=0.93,P=0.216) 之间没有发现显著的因果关系.
- 四种血蛋白 (HYAL1,NMNAT1,IL12RB2,DPP6) 被确定为部分媒介.
结论:
- 遗传证据支持使用类似葡萄糖-1受体激动剂与慢性管间歇性炎风险增加之间的联系.
- 在处方GLP1RAs时,对潜在的风险进行临床评估至关重要.
- 对调解途径的进一步研究可能会为更安全的治疗策略提供信息.
相关概念视频
Glucagon-like Receptor Agonists
850
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
850
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Dipeptidyl Peptidase 4 Inhibitors
596
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
596
Oral Hypoglycemic Agents: Biguanides and Glitazones
587
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
587

